Changes to This Summary (08/08/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Zacharia et al. as reference 8.
Added Clark et al. as reference 8.
Revised text to state that the surgical procedure is followed by radiation therapy, with a 5-year progression-free survival rate of about 70% to 90% and 10-year overall survival rates higher than 90% (cited Merchant et al. as reference 12 and level of evidence 3iDiii). Also added text to state that transient cyst enlargement may be noted soon after radiation therapy but generally resolves without further intervention (cited Shi et al. as reference 14 and level of evidence 3iDiv).
Added Kickingereder et al. as reference 24 and level of evidence 2A.
Added text to state that although systemic therapy is generally not utilized, a small series has shown that the use of subcutaneous pegylated interferon alpha-2b to manage cystic recurrences can result in durable response (cited Yeung et al. as reference 7 and level of evidence 3iiiDiii).
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.